Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IQV Stock Forecast 2025-2026
$154.73
Current Price
$26.75B
Market Cap
Buy 16
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to IQV Price Targets
+73.5%
To High Target of $268.43
+19.6%
To Median Target of $185.00
+2.8%
To Low Target of $159.00
IQV Price Momentum
-1.4%
1 Week Change
+12.7%
1 Month Change
-28.4%
1 Year Change
-21.3%
Year-to-Date Change
-38.8%
From 52W High of $252.88
+14.9%
From 52W Low of $134.65
📊 TOP ANALYST CALLS
Did IQV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if IQVIA is one of their latest high-conviction picks.
Latest IQV Stock Price Targets & Analyst Predictions
Based on our analysis of 42 Wall Street analysts, IQV has a bullish consensus with a median price target of $185.00 (ranging from $159.00 to $268.43). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $154.73, the median forecast implies a 19.6% upside. This outlook is supported by 16 Buy, 7 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Shlomo Rosenbaum at Stifel, suggesting a 2.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IQV Analyst Ratings
16
Buy
7
Hold
0
Sell
IQV Price Target Range
Low
$159.00
Average
$185.00
High
$268.43
Current: $154.73
Latest IQV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IQV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $177.00 |
| May 15, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $190.00 |
| May 7, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $165.00 |
| May 7, 2025 | UBS | Dan Leonard | Buy | Maintains | $185.00 |
| May 7, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $161.00 |
| Apr 25, 2025 | HSBC | Rajesh Kumar | Hold | Downgrade | $160.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $216.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Equal-Weight | Downgrade | $170.00 |
| Apr 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $210.00 |
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Neutral | Maintains | $210.00 |
| Feb 18, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $232.00 |
| Feb 11, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $250.00 |
| Feb 10, 2025 | RBC Capital | Sean Dodge | Outperform | Reiterates | $270.00 |
| Feb 10, 2025 | Truist Securities | Jailendra Singh | Buy | Reiterates | $263.00 |
| Feb 7, 2025 | Stifel | Shlomo Rosenbaum | Buy | Maintains | $261.00 |
| Feb 7, 2025 | UBS | Dan Leonard | Buy | Maintains | $255.00 |
| Feb 3, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $235.00 |
| Jan 21, 2025 | Baird | Eric Coldwell | Neutral | Maintains | $210.00 |
| Dec 20, 2024 | Stephens & Co. | Jeff Garro | Overweight | Initiates | $250.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $235.00 |
Iqvia Holdings Inc. (IQV) Competitors
The following stocks are similar to IQVIA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iqvia Holdings Inc. (IQV) Financial Data
Iqvia Holdings Inc. has a market capitalization of $26.75B with a P/E ratio of 21.1x. The company generates $15.50B in trailing twelve-month revenue with a 8.6% profit margin.
Revenue growth is +2.5% quarter-over-quarter, while maintaining an operating margin of +13.7% and return on equity of +21.6%.
Valuation Metrics
Market Cap
$26.75B
Enterprise Value
$39.42B
P/E Ratio
21.1x
PEG Ratio
12.8x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+2.5%
Gross Margin
+33.9%
Operating Margin
+13.7%
Net Margin
+8.6%
EPS Growth
-13.5%
Financial Health
Cash/Price Ratio
+7.0%
Current Ratio
0.8x
Debt/Equity
242.9x
ROE
+21.6%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iqvia Holdings Inc. (IQV) Business Model
About Iqvia Holdings Inc.
What They Do
Provides analytics and technology solutions for healthcare.
Business Model
Iqvia generates revenue by offering advanced analytics, technology solutions, and contract research services to the healthcare sector, particularly focusing on pharmaceutical, biotechnology, and medical device industries. The company supports drug development through clinical research and regulatory submissions, utilizing AI and machine learning to enhance operational efficiency and patient outcomes.
Additional Information
Iqvia is globally recognized for its extensive data repository and innovative analytical platforms, playing a crucial role in drug safety, patient engagement, and real-world evidence. Its integrated services make it a vital partner for healthcare companies navigating complex markets and regulatory environments.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
88,000
CEO
Mr. Ari Bousbib
Country
United States
IPO Year
2013
Website
www.iqvia.comIqvia Holdings Inc. (IQV) Latest News & Analysis
Latest News
Quick Summary
IQVIA (NYSE:IQV) won the "Best Mobile App for Patient Engagement" at the MedTech Breakthrough Awards for its Health Research Space platform, enhancing patient data collection and engagement.
Why It Matters
IQVIA's award for best mobile app enhances its market position, potentially increasing demand for its services and boosting investor confidence in its growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
IQVIA unveiled new AI agents at GTC Paris, utilizing NVIDIA technology to enhance workflows and insights in life sciences, showcasing their advancements in clinical research services.
Why It Matters
IQVIA's launch of AI agents using NVIDIA technology signals innovation in clinical research, potentially boosting efficiency and profitability in the life sciences sector, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
IQVIA (IQV) is in Phase 18 of its 18-Phase Adhishthana Cycle, indicating potential for movement, though a multi-timeframe analysis suggests a more complex outlook.
Why It Matters
IQVIA's Phase 18 signals potential volatility. A multi-timeframe analysis suggests that investors should be cautious of underlying complexities before making decisions.
Source: Benzinga
Market Sentiment:
Neutral
IQVIA Announces Offering of Senior Notes
19 days ago
Quick Summary
IQVIA Holdings Inc. plans to raise $2 billion through senior notes due 2032. Proceeds will repay existing borrowings and cover offering expenses, with excess for general corporate use.
Why It Matters
IQVIA's $2 billion senior notes offering indicates a strategy to optimize debt management and potentially strengthen its balance sheet, impacting credit ratings and future financing costs.
Source: Business Wire
Market Sentiment:
Neutral
IQVIA Announces Pricing of Senior Notes
18 days ago
Quick Summary
IQVIA Holdings Inc. priced $2 billion in senior notes due 2032. Proceeds will repay existing debt, cover offering expenses, and any excess will be used for general purposes.
Why It Matters
IQVIA's $2 billion senior notes offering indicates a strategy to reduce debt and improve financial stability, which may enhance investor confidence and affect stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
25 days ago
Quick Summary
Rein Therapeutics (NASDAQ: RNTX) has commenced the RENEW Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, with interim data expected in H1 2026.
Why It Matters
The dosing of the first patient in the RENEW Phase 2 trial for LTI-03 signals progress in developing a potential treatment for IPF, which could impact Rein's stock value and future market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IQV Stock
What is Iqvia Holdings Inc.'s (IQV) stock forecast for 2025?
Based on our analysis of 42 Wall Street analysts, Iqvia Holdings Inc. (IQV) has a median price target of $185.00. The highest price target is $268.43 and the lowest is $159.00.
Is IQV stock a good investment in 2025?
According to current analyst ratings, IQV has 16 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $154.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IQV stock?
Wall Street analysts predict IQV stock could reach $185.00 in the next 12 months. This represents a 19.6% increase from the current price of $154.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iqvia Holdings Inc.'s business model?
Iqvia generates revenue by offering advanced analytics, technology solutions, and contract research services to the healthcare sector, particularly focusing on pharmaceutical, biotechnology, and medical device industries. The company supports drug development through clinical research and regulatory submissions, utilizing AI and machine learning to enhance operational efficiency and patient outcomes.
What is the highest forecasted price for IQV Iqvia Holdings Inc.?
The highest price target for IQV is $268.43 from at , which represents a 73.5% increase from the current price of $154.73.
What is the lowest forecasted price for IQV Iqvia Holdings Inc.?
The lowest price target for IQV is $159.00 from Shlomo Rosenbaum at Stifel, which represents a 2.8% increase from the current price of $154.73.
What is the overall IQV consensus from analysts for Iqvia Holdings Inc.?
The overall analyst consensus for IQV is bullish. Out of 42 Wall Street analysts, 16 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $185.00.
How accurate are IQV stock price projections?
Stock price projections, including those for Iqvia Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 21, 2025 3:26 AM UTC